Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Atara Biotherapeutics (ATRA) Accumulated Depreciation & Amortization (2021 - 2025)

Atara Biotherapeutics filings provide 5 years of Accumulated Depreciation & Amortization readings, the most recent being $213000.0 for Q4 2025.

  • On a quarterly basis, Accumulated Depreciation & Amortization fell 98.77% to $213000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $213000.0, a 98.77% decrease, with the full-year FY2025 number at $213000.0, down 98.77% from a year prior.
  • Accumulated Depreciation & Amortization hit $213000.0 in Q4 2025 for Atara Biotherapeutics, down from $404000.0 in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $28.7 million in Q4 2021 to a low of $213000.0 in Q4 2025.
  • Median Accumulated Depreciation & Amortization over the past 5 years was $13.3 million (2023), compared with a mean of $12.1 million.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: rose 29.36% in 2023 and later crashed 98.77% in 2025.
  • Atara Biotherapeutics' Accumulated Depreciation & Amortization stood at $28.7 million in 2021, then crashed by 56.78% to $12.4 million in 2022, then rose by 27.75% to $15.9 million in 2023, then grew by 9.06% to $17.3 million in 2024, then crashed by 98.77% to $213000.0 in 2025.
  • The last three reported values for Accumulated Depreciation & Amortization were $213000.0 (Q4 2025), $404000.0 (Q3 2025), and $375000.0 (Q2 2025) per Business Quant data.